Kulkarni Samarth sold $202K of CRSP

Kulkarni Samarth (Chief Executive Officer) sold 4,098 shares of CRISPR Therapeutics AG (CRSP) at $49.26 ($0.20M total) on 2026-10-14.

Original reporting
SEC EDGAR · Kulkarni Samarth
Published Oct 15, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Neutral
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information via insider selling, but it does not include any operational update, guidance change, or regulatory/clinical catalyst.

02

Market read

Traders may briefly reassess sentiment around CRISPR based on the insider sale, but the impact is likely limited given the modest transaction size and lack of additional news.

03

What to watch

No 10b5-1 plan is stated, so traders may over-interpret intent; also, the article does not disclose total compensation, tax context, or whether other insiders sold/bought around the same time.

Relevance 4/10Novelty 5/10Timing: filed 2026-10-15, transaction dated 2026-10-14

Background

This is an SEC Form 4 insider transaction by CRISPR Therapeutics CEO Kulkarni Samarth.

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

CRISPR Therapeutics CEO Kulkarni Samarth sold 4,098 shares in an open-market transaction worth $201,867.48 on 2026-10-14.

Expected impact

Likely limited downside pressure as traders weigh the insider sale against broader fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but the dollar amount is relatively small and the article provides no accompanying operational or guidance catalyst.

Market effects

Minimal, as this is company-specific insider activity without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs and may not reflect negative expectations, especially without any other negative company news in the filing.

Key entities

  • CRISPR Therapeutics AG

    Company whose CEO filed the Form 4 insider sale.

  • Kulkarni Samarth

    CEO and director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.